



## **Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity**

May 17, 2018

CAMBRIDGE, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and the discovery of M281. The presentation will be part of the 11<sup>th</sup> International Congress on Autoimmunity taking place in Lisbon, Portugal.

### **Presentation Details**

**Presentation Title:** Targeting the Neonatal Fc Receptor (FcRn) for the Treatment of Pathogenic IgG Antibody Diseases

**Session Title:** IVIG MIMETICS: Potential Next Generation Biologics in Autoimmune Diseases

**Presentation Date/Time:** Saturday, May 19, 2018; 5:30 p.m. –5:50 p.m. WEST

**Location:** Auditorium VIII, Parallel Session

**Presenter:** Anthony Manning, Ph.D., Senior Vice President Research, Momenta Pharmaceuticals

The slides will be made available shortly after the presentation on the Momenta Pharmaceuticals website at: <http://ir.momentapharma.com/events-and-presentations>

The presentation will focus on a discussion of the broad potential of FcRn antagonists in rare auto- and allo-immune diseases, and describe details of the discovery and development of M281, Momenta's anti-FcRn therapeutic. The presentation will highlight the unique design attributes of M281, including best-in-class potency and pH insensitivity achieved via proprietary somatic hypermutation technology, fully human IgG scaffold to minimize immunogenic potential, and state-of-art aglycosylation variant design to eliminate any effector function potential. Dr. Manning will present X-ray crystallographic data revealing a unique structural basis for best-in-class affinity, extensive pre-clinical pharmacology and toxicology evaluation, and Phase 1 human clinical trial data that support the potential of M281 as a best-in-class FcRn antagonist.

### **About Momenta**

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at [www.momentapharma.com](http://www.momentapharma.com), which does not form a part of this press release. The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

### **Investor Relations:**

Sarah Carmody

Momenta Pharmaceuticals

1-617-395-5189

[IR@momentapharma.com](mailto:IR@momentapharma.com)

### **Media Relations:**

Karen Sharma

MacDougall Biomedical Communications

1-781-235-3060

[Momenta@macbiocom.com](mailto:Momenta@macbiocom.com)

 [Primary Logo](#)